Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $165 Price Target
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsReiterationPrice Target
Wedbush analyst Martin Fan reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and maintains $165 price target.
Wedbush analyst Martin Fan reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and maintains $165 price target.